Cognition Therapeutics, Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cognition Therapeutics, Inc. (CGTX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $4.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2025-03-20
- Cognition Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $4.00K, a 300.00% increase year-over-year.
- Cognition Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2022-03-31 was $1.00K.
- Cognition Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $4.00K.
- Cognition Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$1.00K.
- Cognition Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2021 was -$11.00K.
- Cognition Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2020 was -$23.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2023-12-31 | $4.00K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $4.00K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $3.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $4.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$1.00K 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$5.00K 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$2.00K 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$11.00K 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $13.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$8.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | -$23.00K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | -$4.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |